Lysine acetylation in obesity, diabetes and metabolic disease

Iyer, Abishek and Fairlie, David P. and Brown, Lindsay (2012) Lysine acetylation in obesity, diabetes and metabolic disease. Immunology and Cell Biology, 90 (1). pp. 39-46. ISSN 0818-9641


Histone acetyltransferases (HATs) and histone deacetylases (HDACs) mediate acetylation and deacetylation of histone proteins and transcription factors. There is abundant evidence that these enzymes regulate the acetylation state of many cytoplasmic proteins, including lysine residues in important metabolic enzymes. Lysine acetylation regulates major cellular functions as a common post-transcriptional modification of proteins, conserved from prokaryotes to humans. In this article, we refer to HATs and HDACs broadly as lysine acetyltransferases (KATs) and deacetylases (KDACs). Lysine acetylation is vitally important in both immunological and metabolic pathways and may regulate the balance between energy storage and expenditure. Obesity, type II diabetes and cardiovascular disease (metabolic syndrome) are widely recognised as features of a chronic low-grade inflammatory state, involving significant alterations in primary immunometabolism. Identifying effective therapeutic and preventive options to treat this multi-factorial syndrome has proven to be very challenging, with an emerging focus on developing anti-inflammatory agents that can combat adiposity and metabolic disease. Here, we summarise current evidence and understanding of innate immune and metabolic pathways relevant to adiposity and metabolic disease regulated by lysine acetylation. Developing this understanding in greater detail may facilitate strategic development of novel and enzyme-specific lysine deacetylase modulators that regulate both metabolic and immune systems.

Statistics for USQ ePrint 20730
Statistics for this ePrint Item
Item Type: Article (Commonwealth Reporting Category C)
Refereed: Yes
Item Status: Live Archive
Additional Information: First published online 15 November 2011. Final publication January 2012. Permanent restricted access to published version due to publisher copyright policy.
Faculty/School / Institute/Centre: Historic - Faculty of Sciences - Department of Biological and Physical Sciences (Up to 30 Jun 2013)
Faculty/School / Institute/Centre: Historic - Faculty of Sciences - Department of Biological and Physical Sciences (Up to 30 Jun 2013)
Date Deposited: 01 Jan 2013 02:07
Last Modified: 05 Feb 2018 05:03
Uncontrolled Keywords: HDAC inhibitor; obesity; metabolic syndrome; diabetes; inflammation; immune
Fields of Research (2008): 06 Biological Sciences > 0699 Other Biological Sciences > 069999 Biological Sciences not elsewhere classified
11 Medical and Health Sciences > 1101 Medical Biochemistry and Metabolomics > 110107 Metabolic Medicine
06 Biological Sciences > 0601 Biochemistry and Cell Biology > 060107 Enzymes
Fields of Research (2020): 31 BIOLOGICAL SCIENCES > 3199 Other biological sciences > 319999 Other biological sciences not elsewhere classified
32 BIOMEDICAL AND CLINICAL SCIENCES > 3205 Medical biochemistry and metabolomics > 320507 Metabolic medicine
31 BIOLOGICAL SCIENCES > 3101 Biochemistry and cell biology > 310106 Enzymes
Socio-Economic Objectives (2008): C Society > 92 Health > 9204 Public Health (excl. Specific Population Health) > 920412 Preventive Medicine
Identification Number or DOI:

Actions (login required)

View Item Archive Repository Staff Only